Aeterna Zentaris Inc. (AEZS): Price and Financial Metrics

Aeterna Zentaris Inc. (AEZS): $0.20

-0.01 (-5.06%)

POWR Rating

Component Grades













Add AEZS to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where AEZS ranks best; there it ranks ahead of 94.69% of US stocks.
  • The strongest trend for AEZS is in Sentiment, which has been heading up over the past 53 days.
  • AEZS ranks lowest in Stability; there it ranks in the 0th percentile.

AEZS Stock Summary

  • With a year-over-year growth in debt of -79.62%, Aeterna Zentaris Inc's debt growth rate surpasses only 3.17% of about US stocks.
  • Revenue growth over the past 12 months for Aeterna Zentaris Inc comes in at -86.41%, a number that bests only 1.23% of the US stocks we're tracking.
  • Aeterna Zentaris Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -105.01%, greater than the shareholder yield of only 3.66% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aeterna Zentaris Inc are ELSE, VOXX, UG, MOG.A, and ITRN.
  • AEZS's SEC filings can be seen here. And to visit Aeterna Zentaris Inc's official web site, go to

AEZS Valuation Summary

  • In comparison to the median Healthcare stock, AEZS's price/sales ratio is 223.68% higher, now standing at 12.3.
  • Over the past 239 months, AEZS's price/earnings ratio has gone up 53.8.
  • AEZS's price/sales ratio has moved up 7.3 over the prior 239 months.

Below are key valuation metrics over time for AEZS.

Stock Date P/S P/B P/E EV/EBIT
AEZS 2021-08-31 12.3 3.4 -8.8 -4.4
AEZS 2021-08-30 11.9 3.3 -8.5 -4.1
AEZS 2021-08-27 12.3 3.4 -8.8 -4.4
AEZS 2021-08-26 12.6 3.5 -9.0 -4.6
AEZS 2021-08-25 12.9 3.6 -9.2 -4.8
AEZS 2021-08-24 11.8 3.3 -8.4 -4.0

AEZS Growth Metrics

    Its 2 year revenue growth rate is now at -86.41%.
  • Its 2 year cash and equivalents growth rate is now at 64.83%.
  • The 2 year price growth rate now stands at -55.06%.
AEZS's revenue has moved down $23,229,000 over the prior 24 months.

The table below shows AEZS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 3.652 -4.129 -5.118
2020-12-31 3.652 -4.129 -5.118
2019-12-31 0.532 -10.725 -6.042
2018-12-31 26.881 6.825 4.187
2018-12-31 26.881 6.825 4.187
2017-12-31 0.923 -22.913 -16.796

AEZS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AEZS has a Quality Grade of F, ranking ahead of 3.18% of graded US stocks.
  • AEZS's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AEZS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.128 0.366 4.492
2020-12-31 0.128 0.366 4.492
2019-12-31 0.024 0.229 2.567
2018-12-31 1.139 0.922 -4.563
2018-12-31 1.139 0.922 -4.563
2017-12-31 0.034 1.000 13.076

AEZS Stock Price Chart Interactive Chart >

Price chart for AEZS

AEZS Price/Volume Stats

Current price $0.20 52-week high $1.15
Prev. close $0.21 52-week low $0.18
Day low $0.19 Volume 490,275
Day high $0.22 Avg. volume 697,424
50-day MA $0.31 Dividend yield N/A
200-day MA $0.46 Market Cap 24.58M

Aeterna Zentaris Inc. (AEZS) Company Bio

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company was founded in 1991 and is based in Summerville, South Carolina.

AEZS Latest News Stream

Event/Time News Detail
Loading, please wait...

AEZS Latest Social Stream

Loading social stream, please wait...

View Full AEZS Social Stream

Latest AEZS News From Around the Web

Below are the latest news stories about Aeterna Zentaris Inc that investors may wish to consider to help them evaluate AEZS as an investment opportunity.

Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually, February 14-17, 2022. In addition to the presentation, m

Yahoo | February 7, 2022

Legacy Financial Advisors, Inc. Buys iShares Core U.S. ...

Investment company Legacy Financial Advisors, Inc. (Current Portfolio) buys iShares Core U.S. Aggregate Bond ETF, WisdomTree Global ex-U.S.

Yahoo | February 4, 2022

Aeterna Zentaris provides pipeline updates

Aeterna Zentaris (AEZS) provided pipeline update and business outlook.Aeterna CEO Klaus Paulini said that in 2021 the company in-licensed six new pre-clinical development programs,…

Seeking Alpha | January 26, 2022

Aeterna Zentaris gets 180-day extension to comply with Nasdaq''s minimum bid price rule

Aeterna Zentaris (AEZS) receives a notice from Nasdaq, which grants an additional 180 calendar days, through Jul

Seeking Alpha | January 26, 2022

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") has notified the Company that it has been granted an additional 180 calendar day period, through July 23, 2022, to evidence compliance wi

Yahoo | January 26, 2022

Read More 'AEZS' Stories Here

AEZS Price Returns

1-mo -35.28%
3-mo -42.05%
6-mo N/A
1-year -76.92%
3-year -93.63%
5-year -79.17%
YTD -43.71%
2021 -16.50%
2020 -53.24%
2019 -69.05%
2018 24.58%
2017 -34.44%

Continue Researching AEZS

Want to see what other sources are saying about Aeterna Zentaris Inc's financials and stock price? Try the links below:

Aeterna Zentaris Inc (AEZS) Stock Price | Nasdaq
Aeterna Zentaris Inc (AEZS) Stock Quote, History and News - Yahoo Finance
Aeterna Zentaris Inc (AEZS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5706 seconds.